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Abstract
Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disease whose
etiopathogenesis remains elusive. The intraneuronal accumulation of hyperphospho-
rylated Tau, a pivotal protein in regulating microtubules (MT), leads to include PSP
into tauopathies. Pathological hallmarks are well known in neural cells but no word
yet if PSP-linked dysfunctions occur also in other cell types. We focused on bone
marrow mesenchymal stromal cells (MSCs) that have recently gained attention for
therapeutic interventions due to their anti-inflammatory, antiapoptotic and trophic
properties. Here, we aimed to investigate MSCs biology and to disclose if any dis-
ease-linked defect occurs in this non-neuronal compartment. First, we found that
cells obtained from patients showed altered morphology and growth. Next, Western
blotting analysis unravelled the imbalance in a-tubulin post-translational modifica-
tions and in MT stability. Interestingly, MT mass is significantly decreased in patient
cells at baseline and differently changes overtime compared to controls, suggesting
their inability to efficiently remodel MT cytoskeleton during ageing in culture. Thus,
our results provide the first evidence that defects in MT regulation and stability
occur and are detectable in a non-neuronal compartment in patients with PSP. We
suggest that MSCs could be a novel model system for unravelling cellular processes
implicated in this neurodegenerative disorder.
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1 | INTRODUCTION
PSP, also known as Richardson-Steele-Olszewski syndrome, is a spo-
radic neurodegenerative disease described for the first time in 19631
and for whom there are not available treatments to date. PSP results
in severe disability, as it is characterized by frequent falls, supranu-
clear vertical gaze palsy, pseudobulbar palsy and rigidity of the
neck.2 Thanks to its wide spectrum of clinical phenotypes, now this
pathology has been recognized as a range of motor and behavioural
syndromes3 and related to multiple pathological mechanisms.4 The
disease is characterized by a neurodegenerative process that
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involves the basal ganglia, the prefrontal cortex and the cerebellum,
with accumulation of tau protein, hence the classification as tauopa-
thy.5 Tau is a MT-binding protein encoded by the MAPT gene into 6
isoforms that are commonly referred to as 3R or 4R (with 3 or 4
MT-binding domains, respectively). Tau binds to and stabilizes MTs,
and promotes MT polymerization.6 The binding to MTs is regulated
by phosphorylation of many residues; indeed, when hyperphospho-
rylated, tau detaches from MTs and accumulates forming neurofibril-
lary tangles (NFTs). All tauopathies are characterized by the
presence of aggregates of abnormally phosphorylated tau protein,
although the isoforms that aggregate vary.7 Both hyperphosphoryla-
tion and accumulation of 4R tau protein in neurons and glia, in basal
ganglia and in the brain stem, are characteristic features of PSP.8 In
PSP, the abnormal phosphorylation of tau triggers its detachment
from MTs, mislocalization from the axon to dendrites and accumula-
tion of still-soluble “oligomers.”9
MTs are cytoskeletal polymers built up by a/b tubulin heterodi-
mers, which participate in many cellular functions, such as mainte-
nance of cell shape, cell migration and intracellular transport. MTs
show a dynamic behaviour, switching between slow growth and
rapid depolymerization10 and are finely regulated by the incorpora-
tion of specific a/b tubulin isotypes, by a plethora of MT-binding
proteins and by tubulin post-translational modifications (PTMs).11,12
Notably, a-tubulin PTMs have been correlated with different MT
subsets: tyrosinated MTs are the most dynamic ones, whereas acety-
lated or detyrosinated MTs are associated with more stable pools.
The wide range of PTMs might, alone or in combination, generate
chemical differences that are sufficient to confer cellular functions
on MTs. Tubulin PTMs have important roles in regulating not only
MT dynamics, but also motor traffic. Interestingly, defects in MT-
based transport in neurons, which are often linked to the accumula-
tion of aggregated proteins, are typical of many neurodegenerative
disorders, including Alzheimer’s13 and Parkinson’s (PD) diseases.14 In
addition, it has been shown that MT stability and PTMs of tubulin
are impaired in human fibroblasts derived from patients with PD.15
For PSP, there are currently no effective symptomatic or dis-
ease-modifying treatments. In the last years, few clinical trials target-
ing mitochondria dysfunction, tau aggregation or MT stability have
been performed or are ongoing.16 Besides other promising drugs,
davunetide, which promotes MT stability, was effective as neuropro-
tective agent in a mouse model of tauopathy17 but it failed in a
phase 2/3 clinical trial on patients with PSP,18 while TPI-287,
another MT stabilizer molecule, has recently entered a phase 1 clini-
cal trial (Trial registration: ClinicalTrials.gov identifier NCT02133846).
Among the ongoing trials, a therapy based on transplantation of
undifferentiated human bone marrow MSCs has been proposed.
MSCs are multipotent cells that can be isolated from many sources
and whose therapeutic relevance is mostly due to their immunosup-
pressive and anti-inflammatory properties.19,20 Interestingly, benefi-
cial effects of intravenous delivery of MSCs have been reported in
rotenone-treated mice, a PD model.21 Starting from encouraging
pre-clinical data, where MSCs show the ability to in vitro rescue 6-
hydroxydopamine-damaged neural cell lines and to synthesize and
secrete neurotrophines,22 we moved to a first pilot phase 1 study. In
this trial, we had the dual aim to assess the safety of MSC therapy
in a “first-in-man” context and the efficacy of autologous MSC treat-
ment. Five patients have been treated in the open phase of our trial
and at the end of this first step, we demonstrated the feasibility of
autologous MSC administration in subjects with PSP and we
recorded a clinical stabilization for at least 6 months (Trial registra-
tion ClinicalTrials.gov NCT01824121).23
To understand the real potential of patient-derived MSCs, we
performed in-depth investigation of their biology. Specifically, we
characterized the MT cytoskeleton of MSCs from patients affected
by PSP, highlighting their characteristics in terms of MT stability and
imbalance in a-tubulin PTMs.
2 | MATERIALS AND METHODS
2.1 | Diagnostic criteria for PSP diagnosis
The criteria used for the diagnosis of PSP followed in this study are
as follows: 1-diagnosis of “probable Progressive Supranuclear
Palsy-Richardson’s disease subtype” according to current diagnostic
criteria,2,24,25 including akinetic-rigid syndrome: gradually progressive
disorder with age at onset of 40 years or later, vertical supranuclear
palsy and prominent postural instability with falls within first year of
disease onset; 2-positive MRI for PSP criteria26; 3-lack of response
to chronic levodopa (at least 12-month treatment).
2.2 | Cell culture, subculture and cumulative
population doublings
MSCs were obtained as previously reported in.22 Briefly, bone mar-
row was obtained after informed consent from aspiration of iliac
crest and directly seeded in alpha-modified Eagle’s medium (alpha-
MEM; Macopharma, Mouvaux, France) supplemented with 10%
high-quality gamma-irradiated foetal bovine serum (FBS) (Thermo
Fisher Scientific, Waltham, MA, USA), at the concentration of
50 000 white blood cell (WBC)/cm2, at 37°C in a humidified atmo-
sphere, 5% CO2. After 72 hours, non-adherent cells were removed
by washing with PBS (Macopharma) with complete medium change.
On day 14, MSCs at P0 were detached using 0.04 mL/cm2 of Try-
pLE™ Select Enzyme (1X) (Thermo Fisher Scientific) and reseeded in
the same culture conditions at the concentration of 4000 MSCs/
cm2. Medium was replaced twice a week. MSCs were subcultured
until they reached a plateau in the growth curve. Population dou-
bling was calculated for each MSC lineage using the following equa-
tion: population doubling = log10(N)/log10(2); where N is the
number of cells harvested at the end of the culture/the number of
seeded cells. To define the expansion potential of cells, cumulative
population doubling (CPD) was calculated by recording the cell
counts and cellular dilution factor at each passage. Cell counting was
performed by Burker chamber using Trypan Blue (Fluka, Buchs,
Switzerland) to discriminate dead cells. For biochemical analyses,
cells at passage 2 (P2) or passage 5 (P5) were seeded in 6-well plates
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at a density of 5000 cells/cm2, whereas for immunofluorescence
staining, 5700 cells/cm2 were seeded in BD Falcon CultureSlide (BD
Bioscience, Jose, CA, USA). Cells were obtained from both controls
(N = 6, age: 66.0  1.18 years) and patients with PSP (N = 10, age:
66.1  1.54 years) (Table 1).
2.3 | Morphometric analysis
For morphometric analyses, 10 random images per well were cap-
tured using a Nikon Eclipse Ti-S microscope (Nikon, Chiyoda, Japan),
and analyses were made using ImageJ software (National Institute of
Health, Bethesda, MD, USA) as previously described.15 For each cell,
the maximum and minimum axes and the cell area were measured.
The ratio between the maximum and minimum axis has been calcu-
lated. Only intact cells fully present into the image were considered.
2.4 | Immunofluorescence
After 48 hours, cells were washed twice with PBS and fixed with
methanol at 20°C. The samples were been treated with 5% BSA
for 15 minutes at room temperature and incubated with the follow-
ing primary antibodies: acetylated a-tubulin mouse IgG (clone 6-11
B-1, SIGMA-Aldrich, Darmstadt, Germany), tyrosinated a-tubulin rat
IgG (clone YL1/2; Abcam, Cambridge, UK), detyrosinated a-tubulin
rabbit IgG (ab48389; Abcam), in PBS, 1% BSA for 1 hour at 37°C.
After washing twice with PBS, samples were incubated with Alexa
Fluor™ 568 anti-rat (Abcam), Alexa Fluor™ 488 anti-mouse (Abcam)
and Alexa Fluor™ anti-rabbit 568 (Abcam) in PBS with 1% BSA for
45 minutes at 37°C. Nuclear staining was made with 40,6-Diamidino-
2-phenylindole dihydrochloride (DAPI) (SIGMA-Aldrich). The cover-
slips were mounted in Mowiol (Calbiochem, Darmstadt, Germany)
—DABCO (SIGMA-Aldrich) and examined with an Axiovert 200 M
microscope (Carl Zeiss, Oberkochen, Germany).
2.5 | Cell extracts
All cellular extracts were prepared in the presence of protease inhibi-
tors (Protease Inhibitor Cocktail, P8340 SIGMA-Aldrich). For prepa-
ration of whole-cell extracts, cells were washed twice with PBS and
scraped into SB1x (2% SDS, 10% glycerol, 5% b-mercaptoethanol,
0.001% bromophenol blue and 62.5 mmol/L Tris, pH 6.8). Protein
concentration was measured with Pierce BCA protein Assay Kit
(Thermo Fisher Scientific). Equal amounts of each sample were sepa-
rated by SDS-PAGE. Cytosolic and cytoskeletal-associated proteins
were separated as previously reported.27 Briefly, cells were rinsed
twice in PEM buffer (10 mmol/L EGTA, 1 mmol/L MgCl2, 88 mmol/
L Pipes, pH 6.94), extracted for 10 minutes at room temperature
with PEM buffer containing 0.1% Triton X-100 and rinsed briefly in
PEM buffer. The obtained Triton X-100-soluble fractions were
diluted 3:1 with SB4x (soluble fraction). The insoluble material
remaining attached to the dish was scraped into SB1x (insoluble
fraction). Equal proportions of each fraction, representing proteins
from the same number of cells, were separated by SDS-PAGE.
2.6 | Western blotting
Protein samples were separated by SDS-PAGE and Western blotted
onto PVDF membrane (Immobilon-P transfer membrane,
IPVH00010; Immobilon-FL IPLL00010; Millipore, Darmstadt, Ger-
many). Membranes were blocked with milk 5%, Tween 0.05% in
Tris-buffered saline (TBS) for 1 hour at room temperature. The mem-
branes were probed over night at 4°C with the following primary
antibodies: a-tubulin mouse IgG (clone B-5-1-2; SIGMA-Aldrich),
acetylated a-tubulin mouse IgG (clone 6-11 B-1; SIGMA-Aldrich),
tyrosinated a-tubulin rat IgG (clone YL1/2; Abcam), detyrosinated a-
tubulin rabbit IgG (ab48389; Abcam). The incubation with secondary
TABLE 1 Demographic and clinical features of investigated
subjects
Healthy
controls
PSP
patients
Number of individuals
(Male/Female)
6 (3/3) 10 (2/8)
Agea (years): Median (range) 66 (62-70) 66 (57-75)
Mean (SEM) 66.0 (1.18) 66.1 (1.54)
Disease onset age (years):
Median (range)
62.5 (54-69)
Mean (SEM) 61.6 (1.25)
Disease durationa (years):
Median (range)
4 (3-7)
Mean (SEM) 4.5 (0.45)
Laterality onset: Left/Rigth/Bilateral 1/1/8
Exposureb: Positive/Negative/n.a. 0/10/0
Smoke: Positive/Negative/n.a. 3/6/1
Familiarityc: Positive/Negative/n.a. 3/5/2
PSP-RSa: Median (range) 48 (35-59)
UPDRS-IIIa: Median (range) 39 (32-51)
Supranuclear vertical gaze
palsya: Positive/Negative/n.a.
9/0/1
Pseudobulbar palsya:
Positive/Negative/n.a.
9/0/1
Rigidity of the necka:
Positive/Negative/n.a.
10/0/0
Pseudobulbar palsy (item 3 PSP-RS):
Median (range)
3 (1-5)
Supranuclear vertical palsy
(item 4 PSP-RS): Median (range)
12 (6-15)
Postural stability (item 30 UPDRS-III):
Median (range)
3 (2-4)
Neck rigidity (item 22 UPDRS-III):
Median (range)
2 (1-4)
n.a., not available; PSP-RS, PSP Rating Scale; UPDRS-III, Unified Parkin-
son’s Disease Rating Scale, part III.
aAt the time of BM collection.
bProfessional exposure to toxic or mutagen substances.
cFamiliarity for neurodegenerative disease.
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antibodies for 1 hour at room temperature was performed using the
following antibodies: anti-mouse IgG HRP-linked antibody (Cell Sig-
naling Technology, Beverly, MA, USA), anti-rabbit IgG HRP-linked
antibody (Pierce, Rockford, IL, USA), anti-rat Alexa Fluor™ 568
(Abcam). Chemiluminescent signals were detected using Supersignal
West Pico Chemiluminescent Substract kit (Pierce). Acquisition and
quantification were performed by Chemidoc and Image Lab software
(Bio-Rad, Hercules, CA, USA).
2.7 | Statistics
Statistical analysis was performed using STATISTICA (StatSoft Inc.,
Tulsa, OK, USA), and significant differences of PSP MSCs vs con-
trol MSCs, or between MSC-A and MSC-B, or between either of
these and control MSCs were assessed by Student’s t-test or one-
way ANOVA with Tukey’s post hoc test, respectively. For
statistical analysis of CPD at single passage between PSP MSCs vs
control MSCs, two-way ANOVA with Sidak’s multiple comparison
test was performed. A P-value <.05 was considered statistically
significant.
2.8 | Study approval
This study was approved by the Ethics Committee of Fondazione
IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Authorization
n.2795) and conforms to the declaration of Helsinki on ethical princi-
ples for medical research involving human subjects.
3 | RESULTS
3.1 | MSCs from patients with PSP show typical
mesenchymal immunophenotyping but have late
defects in proliferative capacity and altered
morphology in culture
To have a comprehensive characterization of MSCs from patients
affected by PSP involved in this study (Table 1), we first evaluated
the expression of many verified and postulated MSC cell surface
antigens by flow cytometry on cultured cell lines at passage 2 (P2) in
culture. In accordance with our previous data,22 their immunopheno-
typic profile confirmed that they are positive for CD90, CD105,
CD73, CD13, CD146, PDGFR, ALP, and negative for CD45, CD34,
CD14, CD3, CD40 and HLA-DR-like cells from age-matched healthy
controls (Table S1 and Figure S1). After that, we investigated the
proliferative capacity of cultured MSCs by measuring the CPD (Fig-
ure 1). MSCs from healthy donors reached an average CPD value of
16 after 11 passages in culture, whereas the CPD of PSP cells
reached the maximum value of 10.2 at passage 9, and then the
curve started to decrease drastically. Moreover, the difference in
growth kinetics between MSCs of patients with PSP and healthy
controls became statistically significant starting from passage 5 (P5),
showing that the in vitro proliferative capacity of MSCs from
patients with PSP was significantly reduced.
Then, we analysed the morphology of cultured MSCs from
patients with PSP and healthy controls at various time-points after
seeding (Figure 2). After 2 hours, cells adhered to the plastic sub-
strate and were round. Six hours after seeding, cells started to lose
their round shape and became elongated; moreover, many cellular
projections were detectable. At later time-points, cells clearly exhib-
ited 2 different shapes: a fibroblast-like morphology (arrow), or a
large, flattened, polygonal or triangle shape (arrowhead), as previ-
ously reported.28 Despite the lack of any differences at first glance
between healthy and PSP cells, detailed morphometric measure-
ments, consisting in the evaluation of the ratio between maximum
and minimum axis (Figure 2B) and the surface area (Figure 2C) of
the cells, were performed. The measurements revealed increase in
the maximum/minimum axis ratio overtime, as expected for elongat-
ing cells, but no actual differences between PSP and control cells.
On the contrary, surface area was significantly increased in PSP cells
compared to control cells at later time-points after seeding. To
exclude that these differences in cellular morphology could be
masked by the large, flattened subpopulation of cells, we restricted
morphometric analysis to the elongated and fibroblast-like cells at
later time-points, and we obtained the same results as in the full
population at 48 hours after seeding (Figure S2). Thus, taken
together, these data show that MSCs from patients with PSP behave
differently in culture as compared to healthy cells.
3.2 | MSCs from patients with PSP show imbalance
in a-tubulin post-translational modifications
The observed changes in the morphology of PSP cells, compared to
healthy controls, prompted us to investigate MT cytoskeleton in
detail. First, we looked at MT architecture by immunodecorating
cells at 48 hours after seeding. In particular, we focused on acety-
lated, detyrosinated and tyrosinated a-tubulin localization. As
reported in Figure 3, tyrosinated a-tubulin was distributed
F IGURE 1 MSCs from patients with PSP show lower and shorter
CPD compared to control cells. Growth kinetics of MSCs from
healthy controls (Ctrl) and PSP patients (PSP) evaluated as CPD. All
values are expressed as mean  SEM. *P < .05, **P < .01,
***P < .001, ****P < .0001 PSP vs Ctrl at the same passage,
according to ANOVA, Sidak’s multiple comparison test. Ctrl: controls
(N = 6); PSP: patients affected by PSP (N = 10)
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throughout the cell both in control and PSP cells, being evident not
only in the central region, where it accumulates, but also in the
periphery. No evident differences were detectable between MSCs of
patients affected by PSP and healthy controls. On the other hand,
acetylated a-tubulin localization was less widespread, being
restricted mainly to the central region of the cell. Moreover,
F IGURE 2 MSCs from patients with
PSP show altered morphology compared to
control cells. Representative phase contrast
micrographs (A) of cultured human MSCs
at different time-points after seeding. Cells
were evaluated just after they started to
attach to the plastic (ie 2 and 6 hours) and
then, when they have already established a
stable connection with the culture surface
(ie 24 and 48 hr). Arrowheads indicate flat
or polygonal cells, arrow indicates
fibroblast-like cell. Scale bar: 100 lm.
Morphometric analysis shows ratio
between maximum and minimum cellular
axes (B) or surface area (C) of MSCs of
healthy controls (Ctrl) and PSP patients
(PSP). *P < .05 PSP vs Ctrl according to
Student’s t-test. All values are expressed as
mean  SEM. Ctrl: controls (N = 6), PSP,
patients affected by PSP (N = 10)
F IGURE 3 MSCs from patients with
PSP show mild perinuclear enrichment of
acetylated tubulin compared to control
cells. Representative immunofluorescence
of MSCs of patients affected by PSP (PSP)
or healthy controls (Ctrl). Forty-eight hours
after seeding, cells were fixed and stained
with anti-acetylated (AcTub, green) or anti-
tyrosinated (TyrTub, red) a-tubulin
antibodies to detect MT cytoskeleton
architecture and tubulin distribution. All
cells were concurrently stained with DAPI
(blue), to visualize the nucleus. Arrowheads
indicate perinuclear enrichment. Scale bar:
20 lm
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acetylated a-tubulin accumulated around the nucleus, especially in
PSP MSCs. In both control and PSP cells, acetylated a-tubulin anti-
body immunodecorated short segments of MTs, while tyrosinated a-
tubulin antibody stains homogenously the MT network (Figure S3),
as reported in other cell types.29 Detyrosinated a-tubulin was not
detectable in immunofluorescence assay (not shown).
Next, to investigate MT subsets in-depth, we analysed the level
of the various a-tubulin PTMs in whole-cell lysates of MSCs of
healthy controls and patients with PSP by Western blotting and den-
sitometric analysis (Figure 4). We analysed cells not only at P2 but
also at P5 in culture, when cells started to proliferate differently
compared to controls (Figure 1).
As reported in Figure 4B, at the earliest time-point, PSP cells
contained as much acetylated and tyrosinated a-tubulin as cells of
healthy controls. Detyrosinated a-tubulin was not detectable by
Western blotting analysis too (not shown). The lack of detyrosinated
a-tubulin in both PSP and controls may be reasonably due to the
particular undifferentiated nature of stromal cells, as this modified
form of a-tubulin is associated with one of the most stable pools of
MTs. The analysis performed at P5 showed enrichment of acetylated
a-tubulin in PSP cells and, in addition, a significant increase in tyrosi-
nated a-tubulin compared to control cells (Figure 4D).
Based on these data, we can conclude that the imbalance in a-
tubulin PTMs becomes evident overtime in PSP cells. As PTMs on a-
tubulin are not merely associated with pools of MT with different
stability, but they are also involved in the maintenance of proper MT
functions, their imbalance could have a strong impact on many cellu-
lar processes.
3.3 | MSCs from patients with PSP show altered
microtubule stability compared to controls
To verify whether the observed differences in tubulin PTMs between
MSCs from patients with PSP and healthy controls correlate with
altered MT stability, we investigated MT mass. By Western blotting
and densitometric analyses (Figure 5), we evaluated the amount of a-
tubulin in the soluble fraction (ie the dimeric pool) and in the insoluble
fraction (ie the polymerized MT fraction) of PSP and control cells. As
reported in Figure 5B, at early passage (P2), the ratio between free a-
tubulin vs a-tubulin incorporated into MTs (Dim/MT) was significantly
increased in PSP cells compared to cells from healthy controls. These
data mean that MSCs from patients with PSP undergo MT destabiliza-
tion, suggesting that defects in the polymerization or depolymerization
of MTs occur. On the contrary, at later passage (P5), a higher Dim/MT
ratio was found in control cells compared to patients with PSP and,
interestingly, compared to P2 controls. Although MT stability remains
unmodified in patients with PSP, the behaviour of control cells
changes overtime. This could indicate that cells isolated from patients
are less prone to undergo MT rearrangements.
Investigating the distribution of Dim/MT ratio values among the
patients, we observed that MSCs from the PSP group could be fur-
ther divided into 2 subgroups: MSC-A (including cells obtained from
PSP#1, #3, #7, #10 patients) and MSC-B (including cells from PSP
#2, #4, #5, #6, #8, #9 patients) as listed in Table S2. As reported in
Figure 5C, at early passage in culture, MSC-B subgroup showed a
Dim/MT ratio similar to the control group, while MSC-A showed a
significant increase in Dim/MT ratio compared to both controls and
F IGURE 4 MSCs from patients affected
by PSP show altered PTMs of a-tubulin
compared to control cells. Representative
immunoblots (A, C) and densitometric
analysis (B, D) of acetylated (AcTub),
tyrosinated (TyrTub) or total (aTub) a-
tubulin protein expression, obtained from
whole-cell extracts of human MSCs from
healthy controls (Ctrl) or PSP patients
(PSP). Cells at early (P2; A and B) or later
(P5; C and D) passages in culture were
lysed and analysed to detect expression
levels of AcTub, TyrTub or total aTub.
Values of each a-tubulin PTM were
normalized on the level of aTub of the
relative sample. Values are expressed as
fold change on control level, error bars
represent SEM. *P < .05 PSP vs Ctrl,
according to Student’s t-test. Ctrl: controls
(N = 6), PSP: patients affected by PSP (P2:
N = 10, P5: N = 8)
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MSC-B subgroup (about 2 folds). Thus, the analysis of MT mass dis-
closed the presence of 2 subgroups of PSP MSCs, one of which
(MSC-A) was characterized by early MT destabilization, whereas the
other one (MSC-B) seemed to be similar to the control group. On
the contrary, looking at later passages in culture, we observed that
MSC-A cells did not show any change, whereas MSC-B cells showed
a significant decrease in Dim/MT ratio when compared to the con-
trol cells.
The assessment of the time course (P2 vs P5) indicated that
Dim/MT ratio does not change overtime in both PSP MSC
subgroups. Thus, the fact that healthy controls were characterized
by an increase in Dim/MT ratio overtime indicates that culture con-
ditions induce MT destabilization per se in control cells. Conversely,
both MSC-A and MSC-B cells did not undergo these changes, sug-
gesting that they are less sensitive to the potential stress induced by
culturing. The 2 subgroups did not differ for any of the other investi-
gated parameters (Figure S4).
All together, these data clearly reveal that MSCs from patients
with PSP are characterized by defects in MT stability regulation
compared to control cells. This suggests that polymerization (or
depolymerization) of MTs may be altered in cells of patients affected
by this neurodegenerative disorder. Although at early time-points, a
subgroup of PSP MSCs (ie MSC-B) showed a similar distribution of
a-tubulin between free and polymerized pools compared to control
cells, we can conclude that the lack of change overtime observed in
both the 2 PSP MSC subgroups clearly supports the concept that
defects in MT stability distinguish PSP MSCs.
4 | DISCUSSION
PSP is a rare neurodegenerative disorder that affects various areas of
the brain, including basal ganglia, brainstem, cerebral cortex, dentate
nucleus and spinal cord regions, and that can affect not only neurons,
but also glial cells.30,31 The mechanism(s) that can lead to PSP are not
yet understood, as well as its causes, that include both environmental
(alkaloids) and genetic (MAPT mutations, haplotype) factors.4 The fact
that an important hallmark of the disease is the presence of abnormal
cerebral aggregates of tau protein, a MT-binding protein, suggests that
MT dysfunction may be an important element of the disease. Obvi-
ously, the difficulty of working on living cells obtained from the
affected brain regions of patients with PSP limits the possibility to
investigate the cellular mechanisms underlying the disease and
prompts the search for reliable human cellular models of the disease.
Here, we investigated MT system in MSCs of patients with PSP and
disclosed significant defects in comparison with healthy controls.
Showing the imbalance of a-tubulin PTMs and the impairment of MT
stability, this study demonstrates for the first time that MT dysfunc-
tion distinguishes PSP MSCs. It also highlights that this signature is
detectable in non-neural and undifferentiated cells such as MSCs.
From a general point of view, MTs are key elements of all the cells,
being responsible for the maintenance of morphology, organelle traf-
ficking and intracellular transport processes, but their importance is
highlighted in cell types with a complex morphological architecture
such as neurons or oligodendrocytes,32,33 which are both involved in
PSP disease. A growing amount of evidence supports the concept that
MT loss, altered MT dynamics and axonal transport defects are linked
to neurodegenerative processes,34,35 and that MT stability could be a
potential therapeutic target.36,37.We investigated MT system in MSCs
moving from the analyses of a-tubulin PTMs to the evaluation of MT
mass. Tubulin PTMs have the potential to generate chemical differ-
ences defining a “tubulin code” on MTs38-40 and, thus, complex molec-
ular signals sufficient to control the interaction of MTs with several
F IGURE 5 Impairment of MT stability is shared by MSCs from
patients with PSP. (A) Representative immunoblot of a-tubulin
(aTub) levels in soluble (Dim) or insoluble (MT) fractions of MSCs of
healthy controls (Ctrl) or PSP-affected patients (PSP) groups, at early
(P2) or later (P5) passages in culture. (B) To evaluate MT mass,
densitometric analysis of aTub levels of each fraction was performed
and the obtained values, expressed as Dim/MT ratio, are shown
graphically. Circles and triangles represent values of single controls
or patients, while the short horizontal lines represent the mean
values within each group. Error bars = SEM. Circles = data obtained
at passage 2 (P2) in culture; triangles = data obtained at passage 5
(P5) in culture. *P < .05, **P < .005 according to Student’s t-test. (C)
Densitometric analysis of aTub levels, expressed as Dim/MT ratio, of
controls and PSP-A subgroup or PSP-B subgroup of patients.
Circles = P2; triangles = P5. *P < .05, **P < .005 according to
ANOVA, Tukey’s post hoc test. Ctrl: controls (N = 6), PSP: patients
affected by PSP (P2: N = 10, P5: N = 9), MSC-A: subgroup A of
patients affected by PSP (N = 4), MSC-B: subgroup B of patients
affected by PSP (P2: N = 6, P5: N = 5)
CALOGERO ET AL. | 7
proteins, including MT-interacting proteins (MIPs) and motor proteins.
On this basis, they are emerging as crucial controllers of MT properties
and functions beyond the well-known role as markers of MTs with dif-
ferent stability. Firstly, we found that detyrosinated a-tubulin is unde-
tectable in MSCs. This finding supports the concept that their MT
cytoskeleton is highly dynamic and lacks long-lived detyrosinated
MTs, as expected in cycling cells. In addition, the levels of tyrosinated
a-tubulin are higher in late passage MSCs derived from patients with
PSP than in those derived from healthy controls. This could suggest
that MT cytoskeleton is more dynamic in patients, tyrosinated a-tubu-
lin being found in the unpolymerized pool of tubulin and in neo-
synthetized MTs, or that cytoskeleton changes its ability to bind MIPs.
Indeed, the C-terminal tyrosine on a-tubulin can act as a binary ON/
OFF switch for the recruitment of MT dynamics regulators, such as
kinesin 13 MCAK, which preferentially depolymerizes tyrosinated
MTs.41 In addition, the C-terminal tyrosine is also required for the
recruitment of MT plus-end-interacting proteins, such as cytoplas-
matic linker protein-170 (CLIP170).42 Therefore, the increasing
amount of tyrosinated a-tubulin that we observed in PSP cells could,
in turn, alter the interactions with various MIPs.
Here, we found that MSCs from patients with PSP are character-
ized by the loss of MT mass at baseline. The ratio between free tubulin
and MTs is altered in PSP cells, tubulin being shifted towards the
unpolymerized pool. This suggests that destabilization of MTs occurs
in PSP cells at baseline. Interestingly, MT mass does not change over-
time in cultured PSP cells, whereas it decreases in control cells, and
this can be read as the inability of patient cells to efficiently remodel
MT cytoskeleton during ageing in culture. Next, we found that PSP
MSCs are heterogeneous in terms of initial MT mass leading us to
identify 2 subgroups. However, this does not weaken the concept that
MT mass regulation/dynamics differ between controls and PSP-
affected patients. Indeed, although one of the MSCs subgroups
resembles controls in terms of initial MT destabilization, they are both
characterized by the absence of changes overtime. This is a very
intriguing point as the detailed clinical evaluation of patients, whose
cells have been included into the 2 subgroups, does not uncover any
difference (Table S2). In addition, deeper investigating our patients for
MAPT gene haplotype, we found that only one (PSP#3, MSC-A
subgroup) shows an allele of H2 haplotype, thus indicating that there
is not a correlation between H1/H2 haplotype distribution and Dim/
MT ratio in any of the 2 MSCs subgroups (Table S3). In conclusion, the
differences highlighted in the MSCs of the 2 subgroups seem to be
not linked with PSP genetic factors or with the clinical features of
patients, but could be the signature that might have the potential to
drive more specific and in-depth stratification of patients.
Speculating about the impact of MT defects on cell functionality,
many are the MT-dependent events in all cell types other than neu-
rons and oligodendrocytes. Among them, intracellular trafficking is
emerging as a key regulator of diverse processes such as cell divi-
sion, migration and secretion, thus confirming that MT dysfunction
could be really detrimental for cells. Defects in the secretion path-
ways could be linked to many neurodegenerative disorders as sug-
gested by recent evidences reporting changes in the serum levels of
modulatory factors in patients affected by PD,43 MSA44 and AD.45
Notably, specific properties of MSCs cells include the secretion of a
set of factors/molecules to the extracellular space, the so-called
secretome, whose crucial role in anti-inflammatory response makes
them a promising therapeutic tool.46 Here, our detailed analysis of
MSCs of patients with PSP unravels MT defects, reduced prolifera-
tive capacity and predisposition to ageing in culture conditions.
Whether these defects can affect their secretory profile and there-
fore to their paracrine reparative effects is still under investigation,
but the clinical use of early passage MSCs is strongly recommended
when autologous MSCs are tested in phase 1/2 clinical trials. Nota-
bly, also in the clinical trial performed by our group based on the
autologous use of MSCs in patients with PSP, the administered cel-
lular products were composed by maximum passage 2 MSCs.22
Peripheral tissues are a source of human living cells, and in the
last few years, they have become reliable models for the identifica-
tion of molecular alterations and possible therapeutic targets in neu-
rodegenerative disorders. For example, skin primary fibroblasts are
considered a good model system for PD47 and, interestingly, we
have previously reported that fibroblasts of patients with PD are
characterized by changes in MT mass compared to controls.15 Focus-
ing on MSCs, they are relatively easy to obtain, to maintain and to
expand in culture. The relevance of studying this cell type for unrav-
elling defects linked to neuronal disorders is completely unexplored.
For this reason, our detailed analysis of MT system is a starting point
for moving to neuronal models obtained from patients that are actu-
ally not available (eg iPSC-derived neurons). Beyond being a poten-
tial model for studying PSP-linked dysfunction, MCSc could be used
for drug screening. Indeed, Polioudaki et al48 showed that taxol and
nocodazole, 2 well-known MT-interacting drugs, can induce moder-
ate and reversible damage to MSCs of healthy donors. As we found
that control and PSP-derived MSCs are characterized by differences
in MT system, it will be intriguing to evaluate if they differently
respond to anti-MT drugs. Thus, MSCs are also a very precious and
promising tool for personalization of drug screening and therapies.
In conclusion, for the first time, our study unravels the character-
istics of MT cytoskeleton in MSCs from patients affected by PSP, a
rare neurodegenerative disorder, and demonstrates that these cells
differ from healthy controls in terms of MT stability, a-tubulin PTMs,
cell morphology and growth. This is in accordance with a very recent
study by a part of our group showing that mitochondrial dysfunction
occurs in MSCs from patients with PSP.49 This suggests that the
mechanisms leading to PSP might also affect undifferentiated non-
neural cells. Our results pave the way to the experimental use of
alternative cellular models as in vitro system for deciphering the
intracellular mechanisms of PSP and identifying novel pharmacologi-
cal targets, thus ultimately helping in finding new therapeutic
approaches to PSP as well as other still orphan neurologic diseases.
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